Abstract: The new use of antagonists of the AMPA receptor complex and its physiologically compatible salts as pharmaceutical agents for prevention and treatment of Parkinson's disease as well as pharmaceutical agents, which contain these compounds, is described.

Abstract: Compounds of formula I ##STR1## are useful for treating TNF-mediated diseases.

Abstract: A pharmaceutically composition for treating MS comprising an effective amount of a combination of a PDE IV inhibitor and an anti-inflammatory and immunomodulatory drug in a pharmaceutically acceptable carrier.

Abstract: This invention relates to (R)-(-)-methylphenyloxazolidinone derivatives, a process for their production and their use as pharmaceutical agents.

Abstract: Described are racemic and enantiomerically pure chiral phenyldihydrofuranones, their preparation and their use in drugs (selective inhibition of the cAMP-specific phosphodiesterase IV).

Abstract: The present invention is a method of preventing or ameliorating the episodic recurrence of MS, comprising administering an effective amount of selective phosphodiesterase inhibitors of Type IV, e.g., Rolipram, e.g., wherein the severity of the episodic recurrences is ameliorated or the time period between episodes is lengthened.

Abstract: The present invention is a method of preventing or ameliorating the episodic recurrence of MS, comprising administering an effective amount of selective phosphodiesterase inhibitors of Type IV, e.g., Rolipram, e.g., wherein the severity of the episodic recurrences is ameliorated or the time period between episodes is lengthened.

Abstract: 8.alpha.-acylamino ergolines are useful dopamine agonists.

Abstract: Compounds of formula I and their acid addition salts ##STR1## in which R.sup.2 R.sup.6 R.sup.13 and X have the meanings defined herein are described as well as a process and intermediates for their production, and pharmaceutical agents containing these compounds.

Abstract: 2,14-Disubstituted ergolines of formula I ##STR1## in which R, R.sup.2, R.sup.6, R.sup.14 and X have the meaning named in the application, as well as their production and use in pharmaceutical agents, are described.

Abstract: Compounds of general Formula I labeled with 7.sup.5 Br, .sup.76 Br, .sup.77 Br, .sup.80m Br or .sup.80 Br isotopes ##STR1## wherein R.sup.6 is a C.sub.1-6 hydrocarbon residue and C.sub.2 C.sub.3, C.sub.9 C.sub.10 is a single or a double bond, as well as their acid addition salts, as diagnostic media to image dopamine.

Abstract: Compounds of formula I ##STR1## in which R.sup.2 means optionally substituted C.sub.1-7 alkyl, C.sub.2-7 alkenyl, CH.sub.2 --O--C.sub.1-4 alkyl or CH.sub.2 --S--C.sub.1-4 alkylR.sup.6 means C.sub.2-6 alkyl, C.sub.3-6 alkenyl or C.sub.3-5 -cycloalkyl-C.sub.1-2 alkyl andR.sup.8 means CH.sub.2 --X, ##STR2## in which X stands for CN, OCH.sub.3, SCH.sub.3 or CONH.sub.2 and R.sup.1 stands for hydrogen, halogen, methyl or methoxy, and R.sup.3 and R.sup.4 each mean C.sub.1-4 alkyl or (CH.sub.2).sub.n --N(CH.sub.3).sub.2, in which n=1-4, and their acid addition salts, the process for their production, their use as pharmaceutical agents as well as intermediate compounds are described.

Abstract: 8.alpha.-acylamino ergolines are useful dopamine agonists.

Abstract: 2-Substituted ergolines ##STR1## wherein C.sub.2 C.sub.3 and C.sub.9 C.sub.10 represent a single of double bond;X is oxygen or sulfur;R.sup.2 is C.sub.1-10 alkyl, optionally halogen-substituted C.sub.2-10 alkenyl, CH.sub.2 YR.sup.3, CR.sup.12 (OR.sup.4)R.sup.5, CH.sub.2 --CHR.sup.9 --COR.sup.10 or COR.sup.12,whereinY is oxygen or sulfur,R.sup.3 is hydrogen, C.sub.1-4 alkyl, phenyl, C.sub.2-5 acyl or phenyl C.sub.1-4 alkyl,R.sup.4 is hydrogen or C.sub.2-5 acyl,R.sup.5 is C.sub.1-9 alkyl,R.sup.9 is COCH.sub.3 or COO-C.sub.1-4 alkyl,R.sup.10 is C.sub.1-4 alkyl or O-C.sub.1-4 alkyl,R.sup.12 is hydrogen or C.sub.1-9 alkyl; andR.sup.6 is C.sub.2-10 alkyl, C.sub.3-10 alkenyl or C.sub.4-10 cycloalkyl-C.sub.1-3 -alkyl,and acid addition salts, isomers and isomeric mixtures thereof are dopaminergic agonists and useful for treating Parkinson's Disease.

Abstract: Compounds of general Formula I are disclosed ##STR1## wherein R.sup.1 is C.sub.1-4 -alkyl,R.sup.3 is hydrogen, C.sub.1-4 -alkyl, acyl, aryl,R.sup.5 is hydrogen, C.sub.1-4 -alkyl,X is oxygen, CH.sub.2 or NR.sup.4 with R.sup.4 =hydrogen, C.sub.1-4 -alkyl andY is an aromatic or nonaromatic ring system which can optionally contain one to two hetero atoms and can be substituted, and the stereoisomers and their mixtures,as well as their preparation and use as medicinal agents.

Abstract: The invention relates to a method of treating dementia, such as cerebro-vascular dementia, for example, multiple infarct dementia and amyloid angiopathic dementia, cerebro-parenchymatous dementia, such as Alzheimer's dementia and Pick's disease, and dementia caused by brain tumor, hydrocephalus, hepatic meningitis, cerebral trauma, or cerebral function disorders, comprising administering rolipram.

Abstract: 2-Substituted ergolines ##STR1## wherein C.sub.2 C.sub.3 and C.sub.9 C.sub.10 represent a single or double bond;X is oxygen or sulfur;R.sup.2 is C.sub.1-10 alkyl, optionally halogen-substituted C.sub.2-10 alkenyl, CH.sub.2 YR.sup.3, CR.sup.12 (OR.sup.4)R.sup.5, CH.sub.2 -CHR.sup.9 -COR.sup.10 or COR.sup.12, whereinY is oxygen or sulfur,R.sup.3 is hydrogen, C.sub.1-4 alkyl, phenyl, C.sub.2-5 acyl or phenyl C.sub.1-4 alkyl,R.sup.4 is hydrogen or C.sub.2-5 acyl,R.sup.5 is C.sub.1-9 alkyl,R.sup.9 is COCH.sub.3 or COO-C.sub.1-4 alkyl,R.sup.10 is C.sub.1-4 alkyl or O-C.sub.1-4 alkyl,R.sup.12 is hydrogen or C.sub.1-9 alkyl; andR.sup.6 is C.sub.2-10 alkyl, C.sub.3-10 alkenyl or C.sub.4-10 cycloalkyl-C.sub.1-3 -alkyl,and acid addition salts, isomers and isomeric mixtures thereof are dopaminergic agonists and useful for treating Parkinson's Disease.

Abstract: The enzyme cofactor nicotinamide adenine dinucleotide or a salt thereof is useful for the treatment of Parkinson's disease.

Abstract: Benzimidazole derivatives of general Formula I ##STR1## wherein R.sup.1 and R.sup.2, being identical or different, each mean hydrogen or an optionally substituted hydrocarbon residue andX is oxygen or sulfur,as well as the acid addition salts thereof, are useful, e.g., as dopaminergic agents.

Abstract: The disclosure relates to 1,2-substituted ergoline derivatives of general Formula I ##STR1## wherein X is an oxygen or sulfur atom,R.sup.1 is a lower alkyl group,R.sup.2 is halogen, acyl, a saturated or unsaturated lower alkyl group which can optionally be substituted by OR.sup.4 wherein R.sup.4 is hydrogen, lower alkyl, tetrahydropyranyl or cycloalkyl, or by an optionally substituted aryl residue, an S-R.sup.5 -group wherein R.sup.5 means a lower alkyl group which can optionally be substituted by aryl or an optionally substituted aryl residue, a ##STR2## wherein n=2 o4 3, or a --CHO-group, R.sup.3 is lower alkyl or acyl, andC.sub.9 -C.sub.10 is a CC-single or a CC-double bond, and the hydrogen atom in the 10-position is in the .alpha.-location if C.sub.9 -C.sub.10 is a CC-single bond, as well as the acid addition salts thereof. The compounds exhibit valuable pharmacological properties.